- Home
- ENTX vs CDTX Comparison
ENTX vs CDTX Comparison
Compare ENTX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- CDTX
- Stock Information
- Founded
- ENTX 2010
- CDTX 2012
- Country
- ENTX Israel
- CDTX United States
- Employees
- ENTX N/A
- CDTX N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTX Health Care
- CDTX Health Care
- Exchange
- ENTX Nasdaq
- CDTX Nasdaq
- Market Cap
- ENTX 67.2M
- CDTX 79.3M
- IPO Year
- ENTX 2018
- CDTX 2015
- Fundamental
- Price
- ENTX $1.73
- CDTX $14.37
- Analyst Decision
- ENTX Strong Buy
- CDTX Strong Buy
- Analyst Count
- ENTX 1
- CDTX 5
- Target Price
- ENTX $10.00
- CDTX $30.50
- AVG Volume (30 Days)
- ENTX 127.7K
- CDTX 21.1K
- Earning Date
- ENTX 11-08-2024
- CDTX 11-07-2024
- Dividend Yield
- ENTX N/A
- CDTX N/A
- EPS Growth
- ENTX N/A
- CDTX N/A
- EPS
- ENTX N/A
- CDTX N/A
- Revenue
- ENTX $99,000.00
- CDTX $44,653,000.00
- Revenue This Year
- ENTX N/A
- CDTX N/A
- Revenue Next Year
- ENTX N/A
- CDTX N/A
- P/E Ratio
- ENTX N/A
- CDTX N/A
- Revenue Growth
- ENTX 607.14
- CDTX 19.60
- 52 Week Low
- ENTX $0.52
- CDTX $10.00
- 52 Week High
- ENTX $3.35
- CDTX $24.40
- Technical
- Relative Strength Index (RSI)
- ENTX 44.32
- CDTX 72.85
- Support Level
- ENTX $1.64
- CDTX $12.89
- Resistance Level
- ENTX $1.80
- CDTX $13.78
- Average True Range (ATR)
- ENTX 0.09
- CDTX 0.70
- MACD
- ENTX -0.01
- CDTX 0.13
- Stochastic Oscillator
- ENTX 30.00
- CDTX 75.31
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.